Table 1.
Baseline characteristics of the patients. BMI Body Mass Index, ECOG the Eastern Cooperative Oncology Group, ER estrogen receptor, PR progesterone receptor, HER2 human epidermal growth factor receptor 2, FISH fluorescence in situ hybridization, AR androgen receptor, pCR pathological complete response, TCHP taxanes, carboplatin, trastuzumab and pertuzumab, NPHP N: vinorelbine 25–30 mg/m2 administered by intravenous infusion on day 1 and day 8 every 3 weeks; P: cisplatin 75 mg/m2 administered by intravenous infusion, completed in 2–3 days, every 3 weeks; H: trastuzumab; P: pertuzumab.
| Characteristic | n = 44 |
|---|---|
| Sex | |
| Female | 44 (100%) |
| Male | 0 (0%) |
| Age, years | 47.95 (24–68) |
| BMI | 23.59 (16.77–36.44) |
| Menopausal status | |
| Premenopausal | 27 (61.4%) |
| Postmenopausal | 16 (36.4%) |
| Unknown | 1 |
| Molecular subtype | |
| HER2 overexpressed | 23 (52.3%) |
| Luminal B HER2 positive | 21 (47.7%) |
| ECOG performance status at enrollment | |
| 0 | 43 (97.7%) |
| 1 | 1 (2.3%) |
| T stage | |
| T1 | 1 (2.3%) |
| T2 | 36 (81.8%) |
| T3 | 7 (15.9%) |
| N stage | |
| N0 | 22 (50%) |
| N+ | 22 (50%) |
| Histological grade | |
| 2 | 19 (43.2%) |
| 3 | 24 (54.5%) |
| Unknown | 1 |
| Histological score | |
| 6 | 10 (22.7%) |
| 7 | 8 (18.2%) |
| 8 | 15 (34.1%) |
| 9 | 9 (20.5%) |
| Unknown | 2 |
| ER | |
| <1% | 23 (52.3%) |
| ≥1% | 21 (47.7%) |
| PR | |
| <1% | 29 (65.9%) |
| ≥1% | 15 (34.1%) |
| ER/PR expression | |
| ER-PR- | 23 (52.3%) |
| ER + PR- | 6 (13.6%) |
| ER+ PR+ | 15 (34.1%) |
| HER2 | |
| 3+ | 37 (84.1%) |
| 2+ and FISH+ | 7 (15.9%) |
| Ki-67 | |
| <30% | 5 (11.4%) |
| ≥30% | 38 (86.4%) |
| Unknown | 1 |
| AR | |
| 0 | 6 (13.6%) |
| ≥1% | 38 (86.4%) |
| <50 | 7 (18.4%) |
| 50–90 | 13 (34.2%) |
| ≥90 | 18 (47.49%) |
| Neoadjuvant therapy | |
| TCHP | 40 (90.9%) |
| NPHP | 4 (9.1%) |
| Pathological response | |
| pCR | 22 (50.0%) |
| Non-pCR | 22 (50.0%) |